

EXECUTIVE SUMMARY

First half 2025



Main figures €Mn

Op. Revenue	EBITDA	EBIT
314.6 (-4%)	65.6 (-6%)	50.9 (-10%)
Net profit	Capex	Net debt
39.7 (-10%)	20.8 (+12%)	79.7

2025 operating revenue guidance:
Decrease by a mid-single-digit percentage vs 2024

- ✓ ROVI acquires a majority position in Cells IA Technologies, S.L.
- ✓ Final Decision to award aid of €36.3 Mn for ROVI's LAISOLID project subsidised by the CDTI.




Funded by
the European Union
NextGenerationEU



GOBIERNO DE ESPAÑA
MINISTERIO DE CIENCIA, INNOVACIÓN Y UNIVERSIDADES



Operating revenue €Mn




CDMO business Specialty pharmaceutical business

Specialty pharma business €Mn

Total
€237.4m

+13%



Heparin franchise*

43% of operating revenue

€135.2m

+12%

Enoxaparin sales

€79.8m

+14%

- ✓ Sales of enoxaparin increased mainly to the increase in orders from international partners in H1 2025.
- ✓ ROVI expects full year sales to increase by a mid-single-digit percentage in 2025 vs to 2024.

Bemiparin sales

€51.5m

+9%

- ✓ Sales of bemiparin were mainly driven by international sales which increased by 38% in the period.
- ✓ ROVI expects full year sales to increase by a low-single-digit percentage in 2025 vs 2024.

* LMWH (Bemiparin and Enoxaparin biosimilar) + other heparins

Other prescription-based pharmaceutical products

Neparvis®

€27.7m

+11%

Okedi®

€26.9m

+115%

- ✓ Risperidone ISM®, a LAI of risperidone for schizophrenia.
- ✓ Marketed in Europe, Australia & Taiwan.

CDMO⁽¹⁾ business €Mn

Total
€77.2m


-35%




⁽¹⁾Contract Development and Manufacturing Organisation

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 34-38) of the press release on the financial results for the first half of 2025. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders-investors/financial-business-information>


Gross profit €Mn



SG&A expenses €Mn



EBITDA €Mn



R&D expenses €Mn €16.8

+38%


Product	Potential Indication	Current Situation	Key Milestones
Okedi® Risperidone, monthly	Schizophrenia	Approved	Marketed in Europe, and in Australia & Taiwan
Letrozole ISM®, annual	Breast Cancer	Clinical development on hold	Phase I: Superior oestrogen suppression vs Femara®
Letrozole SIE ⁽¹⁾ , quarterly	Breast Cancer	Completion of phase I	Phase I: positive readout confirms superior estrogen suppression vs Femara® and allows progression to phase III clinical trial
Risperidone, quarterly	Schizophrenia	Completion of phase I	Phase I: positive readout allows progression to phase III clinical trial
Concentrated on improving posology for already approved compounds, which benefits risk / reward profile Multiple FDA / GMP approved facilities to support the platform			

(1) Superior Inhibition of Estrogen

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 34-38) of the press release on the financial results for the first half of 2025. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders-investors/financial-business-information>

EBITDA Pre-R&D⁽¹⁾ €Mn €82.4m +0.4%

Net profit €Mn



(1) Calculated excluding R&D expenses in H1 2025 and H1 2024

News flow

SPECIALTY PHARMA

- ✓ Additional new products to be launched
- ✓ Granting by the competent local authorities of the marketing authorisation of an Enoxaparin biosimilar outside Europe

CDMO

- ✓ Moderna's product manufacturing progress
- ✓ Announcement of new contracts

ISM® Technology Platform

- ✓ Launch of Okedi® in Europe, and rest of the world
- ✓ Phase III efficacy clinical trial and pk/ bioavailability study of a new three-monthly formulation of letrozole (Letrozole SIE)
- ✓ Phase III efficacy clinical trial and pk/ bioavailability study of risperidone for a 3-monthly injection